menu search

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Company preparing to initiate Phase 3 clinical trials of TTP399, an adjunctive therapy to insulin, for the treatment of Type 1 diabetes Biotech industry and Wall Street veteran Steven Tuch appointed Executive Vice President and Chief Financial Officer Biotech industry veteran Elizabeth Keiley appointed Executive Vice President and General Counsel HIGH POINT, N.C., March 06, […] The post vTv Therapeutics Announces 2022 Fourth Quarter and Full Year Financial Results and Provides Corporate Update a... Read More
Posted: Mar 6 2023, 22:56
Author Name: forextv
Views: 082115

Search within

Pages Search Results: